Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

The Antiretroviral Pipeline

September 2011

 < Prev  |  1  |  2  |  3  |  4  |  5 

References

CROI: Conference on Retroviruses and Opportunistic Infections.
IAS: International AIDS Society
ICAAC: Interscience Conference on Antimicrobial Agents and Chemotherapy

  1. Based on the US AIDS Drug Assistance Programme (ADAP) waiting list April 2010-April 2011. http://www.nastad.org.
  2. Fair Pricing Coalition brokers rescue of troubled ADAP; nearly 6,500 Floridians will continue to receive HIV medications. Fair Pricing Coalition press statement. (1 February 2011).
  3. London HIV Consortium issues new guidelines for ARV prescribing. HIV Treatment Bulletin. March/April 2011.
  4. US government leading backlash against AIDS funding.
  5. "PEPFAR makes U-Turn in Uganda. 4/8/10" 4 August 2010.
  6. Emanuel Z. The HIV/AIDS fight needs cooperation, not division. Huffington Post. 21 July 2010.
  7. Bongaarts J, Mead O. Global HIV/AIDS policy in transition. Science, Vol. 328 no. 5984 pp. 1359-1360. (1 June 2010).
  8. Sachs J. The MDG decade: looking back and conditional optimism for 2015. Lancet 2010; 376: 950-951.
  9. HPTN press release. Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052): 96% reduction in HIV transmission, according to study conducted by HIV Prevention Trials Network. 12 May 2011.
  10. NIAID. Q&A: The HPTN 052 Study: Preventing Sexual Transmission of HIV with ANTI-HIV Drugs.
  11. UNAIDS annual portrait of the global AIDS epidemic. November 2010.
  12. EMA issue restricted indication for d4T (stavudine). Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 February 2011. Questions and answer document.
  13. Approval of Edurant (rilpivirine) a new NNRTI) for the treatment of HIV in treatment naive patients. 20 May 2011.
  14. Gilead press release. US food and drug administration approves Gilead sciences' Complera, a new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naive adults. (10 August 2011). Prescribing information.
  15. Approval of Viramune XR (nevirapine) 400 mg extended release tablet. FDA list serve. (25 March 2011).
  16. Gilead press release. Phase III clinical trial of Gilead's investigational elvitegravir meets 48-week primary objective. (23 March 2011).
  17. Elion R et al. The single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (QUAD) maintains a high rate of virologic suppression, and cobicistat is an effective pharmacoenhancer through 48 weeks. 50th ICAAC, 12-15 September 2010, Boston. Abstract H-938b.
  18. Gilead press release. Gilead's single-tablet "Quad" HIV regimen maintains high viral suppression through 48 weeks in phase II study. (13 September 2011).
  19. Cohen C et al. Randomized, phase II evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 27 March 2011 - Volume 25 - Issue 6 - p F7-F12.
  20. Eron J et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. 18th CROI, 27 February-3 March 2011, Boston. Abstract 151LB.
  21. ViiV press release. (11 February 2011).
  22. Clinical trials registry. Lersivirine 48 week study extended. http://clinicaltrials.gov/ct2/show/NCT01254656?term=NCT01254656&rank=1 http://clinicaltrials.gov/ct2/results?term=Lersivirine
  23. Mori J et al. Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, UK. 7-11 November 2010. Oral abstract O_49.
  24. Nettles R et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068: a potentially first-in-class oral HIV attachment inhibitor. 18th CROI, 27 February-3 March 2011, Boston. Oral abstract 49.
  25. Nowicka-Sans B et al. Antiviral activity of a new small molecule HIV-1 attachment inhibitor, BMS-626529, the parent of BMS-663068. 18th CROI, 27 February-3 March 2011, Boston. Poster 518.
  26. Merck press release. Merck decides to stop development of vicriviroc for treatment of HIV. (14 July 2011).
  27. Myriad Pharmaceuticals announces intent to focus on oncology portfolio. (8 June 2010).
  28. ClinicalTrials.gov listings.
  29. Martin D et al. TBR-652 absorption, distribution, metabolism, and excretion profile in rats, dogs, monkeys, and humans. 18th CROI, 27 February-3 March 2011, Boston. Poster abstract 627.
  30. Efficacy, safety, and tolerability of cenicriviroc (CVC) in combination with Truvada or Sustiva plus Truvada in HIV 1-infected, antiretroviral treatment-naive, adult patients infected with only CCR5-tropic virus.
  31. Chimerix's antiviral CMX157 demonstrates positive phase I results with favorable pharmacokinetics, safety & tolerability: exhibits potent in vitro activity against XMRV and highly resistant HIV. Chimerix press release. (13 December 2010).
  32. ViiV Healthcare pipeline. (Accessed 26 April 2011).
  33. A study to determine the antiviral activity of TMC310911 when administered with ritonavir in treatment-naive HIV-1-infected patients. (Accessed 26 April 2011).
  34. Markowitz M et al. GS-7340 demonstrates greater declines in HIV-1 RNA than TDF during 14 days of monotherapy in HIV-1-infected subjects. 18th CROI, 27 February-3 March 2011, Boston. Oral abstract 152LB.
  35. Lee W et al. In vivo and in vitro characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of tenofovir; selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. 9th CROI 24-28 February 2002, Seattle. Poster abstract 384.
  36. Bristol-Myers Squibb and Oncolys BioPharma enter global licensing agreement for investigational HIV compound. BMS press statement. (20 December 2010). www.oncolys.com/en/our_news/01.html, www.bms.com/partnering/Pages/news.aspx
  37. L Cotte et al. A phase-Ib/IIa dose-escalation study of OBP-601 (4'-ethynyl-d4T, festinavir) in treatment-experienced, HIV-1-infected patients. 50th ICAAC, 12-15 September 2010, Boston. Abstract H-933.
  38. Weber J et al. Drug susceptibility profile of OBP-601, a novel NRTI, using a comprehensive panel of NRTI- or NNRTI-resistant viruses. 15th CROI, 3-6 February 2008, Boston. Poster 726b.
  39. Prescribing information for Edurant (rilpivirine) [Tablets] Initial US Approval: 2011.
  40. Cohen C et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. 18th IAS Conference, 18-23 July 2010, Vienna. Oral abstract late breaker THLBB206. Webcast: http://pag.aids2010.org/flash/?pid=113137
  41. Rimsky L et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase III studies ECHO and THRIVE. 50th ICAAC, 12-15 September 2010, Boston. Abstract H-1810.
  42. Arribas J et al. Lipid profiles of TMC278 and EFV in treatment-naive HIV-1+ patients: pooled week-48 data from the randomized double-blind phase III ECHO and THRIVE trials. Poster abstract 819.
  43. Wohl D et al. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. Abstract 79LB.
  44. Mills A et al. Neurologic and psychiatric safety profile of TMC278 compared with EFV in treatment-naive HIV-1+ patients: ECHO and THRIVE Trials at 48 Weeks. Poster abstract 420.
  45. Mathias A et al. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF. 18th IAS Conference, 18-23 July 2010, Vienna. Oral abstract late breaker LBPE17.
  46. Molina J-F et al. Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study. Oral late breaker abstract WELBB05. Webcast: http://pag.ias2011.org/flash.aspx?pid=611
  47. German P et al. The effect of cobicistat on cytochrome P450 2D6, 2B6 and P-glycoprotein using phenotypic probes. 12th International Workshop on Clinical Pharmacology of HIV Therapy, 13-15 April 2011, Miami. Oral abstract O_1.
  48. Gilead press release. Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize a New Fixed-Dose Combination of Cobicistat and Prezista. (28 June 2011).
  49. Nettles R et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068: a potentially first-in-class oral HIV attachment inhibitor. 18th CROI, 27 February-3 March 2011, Boston. Oral abstract 49.
  50. Nowicka-Sans B et al. Antiviral Activity of a New Small Molecule HIV-1 Attachment Inhibitor, BMS-626529, the Parent of BMS-663068. 18th CROI, 27 February-3 March 2011, Boston. Poster 518.
  51. Zhu L et al. Exposure-response analyses of an oral attachment inhibitor BMS-663068 following 8 days of monotherapy in HIV-infected patients. 12th International Workshop on Clinical Pharmacology of HIV Therapy, 13-15 April 2011, Miami. Oral abstract O_8.
  52. Eron J et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. 18th CROI, 27 February - 3 March 2011, Boston. Abstract 151LB.
  53. Shionogi-ViiV Healthcare press release. Clinical programme for investigational once-daily HIV integrase inhibitor - phase III treatment-naive and treatment-experienced trials underway for S/GSK1349572 ('572). 21 October 2010.
  54. Van Lunzen J et al. Rapid, robust and sustained antiviral response with once-daily (QD) dolutegravir (DTG, S/GSK1349572), a next generation integrase inhibitor (INI) in combination therapy in antiretroviral-naive adults: 48 week results from SPRING-1 (ING112276). Oral abstract TUAB0102. Webcast: http://pag.ias2011.org/flash.aspx?pid=293
  55. Shionogi-ViiV Healthcare press release. Shionogi-ViiV Healthcare starts phase III trial for "572-Trii" fixed-dose combination HIV therapy. (3 February 2011).
  56. Mori J. Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile. 10th International HIV Congress, 7-11 November 2010, Glasgow. Abstract and webcast.
  57. Pozniak A et al. Efficacy and safety of lersivirine (UK-453,061) vs. efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicentre, randomised, double-blind, phase IIb trial (study A5271015). Oral Abstract TUAB0101. Webcast: http://pag.ias2011.org/flash.aspx?pid=294
  58. Martin DE et al. TBR-652, a potent dual chemokine receptor 5/chemokine receptor 2 (CCR5/CCR2) antagonist in phase II development for treatment of HIV infection. 18th IAS Conference, 18-23 July 2010, Vienna. Oral abstract MOAB0104.
  59. Avexa press statement. Avexa and FDA agree path forward for ATC.
  60. Forssmann W-G et al. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med 22 December 2010: Vol. 2, Issue 63, p. 63re3.
  61. Nathans R et al. Small-molecule inhibition (by RN-18) of HIV-1 Vif. Research letter. Nature Biotechnology 26, 1187 - 1192 (2008).
  62. Albin JS et al. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem. 2010 Dec 24;285(52):40785-92.
  63. University of Minnesota press release. U of M scientist gets five-year, $10 million grant to direct innovative HIV research program. (18 April 2011).
  64. Blair WS et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog 6(12): e1001220.doi:10.1371/journal.ppat.1001220.
  65. Chamanian M et al, Unique inhibition of HIV-1 reverse transcription by a cyclic peptide designed as a mimic to the TAR RNA binding site in the HIV-1 Tat protein. Frontiers in HIV Drug Development (HIV DART), 7-10 December 2010, Los Cabos, Mexico. Abstract 29.
  66. Lansdon EB et al. Structural and binding analysis of HIV-1 RNase H inhibitors targeting active site metals. Frontiers in HIV Drug Development (HIV DART), 7-10 December 2010, Los Cabos, Mexico. Abstract 32.
  67. Mphahlele MK et al. Inhibition of reverse transcriptase activity by gold-based compounds. Frontiers in HIV Drug Development (HIV DART), 7-10 December 2010, Los Cabos, Mexico. Abstract 52.
  68. Mallipeddi R and Rowan LC. Progress in antiretroviral drug delivery using nanotechnology. International Journal of Nanomedicine 2010:5 533-547. Online open access.
  69. Mamo T et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (London). 2010 February; 5(2): 269-285.
  70. Personal communication, Dr. Alejandro Sosnik, University of Buenos Aires. (June 2011).
 < Prev  |  1  |  2  |  3  |  4  |  5 


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Treatment Action Group and HIV i-Base. It is a part of the publication 2011 Pipeline Report.
 
See Also
More on HIV Medications
HIV Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement